DYNE THERAPEUTICS, INC.
Ownership & governance
Executives 5Directors 10Avg age 60Avg tenure 3.5y
JC
John Cox
Chief Executive Officer
Age 63Since 2024-03-24Profile →
+14
Executives5
JC
John Cox→
Chief Executive Officer
Age 63Since 2024-03-24
EL
Erick Lucera→
Director of Finance/CFO
Age 58Since 2025-03-30
RB
Ranjan Batra
Chief Tech/Sci/R&D Officer
—Since 2025-04-27
DK
Douglas Kerr→
Chief Tech/Sci/R&D Officer
Age 59Since 2024-09-02
RM
Raj Manchanda
Chief Tech/Sci/R&D Officer
Age 60Since 2025-03-31
Board of directors10
EH
Edward Hurwitz→
Director/Board Member
Age 62Since 2018-10-31
JR
Jason Rhodes→
Chairman
Age 56Since 2018-10-31
DK
Dirk Kersten→
Director/Board Member
Age 51Since 2018-10-31
CS
Catherine Stehman-Breen→
Director/Board Member
Age 63Since 2019-05-31
DL
David Lubner→
Director/Board Member
Age 61Since 2020-02-29
CI
Carlo Incerti→
Director/Board Member
Age 67Since 2022-03-01
JC
John Cox→
Director/Board Member
Age 63Since 2024-03-24
BP
Brian Posner→
Director/Board Member
Age 64Since 2025-09-30
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| T. Rowe Price Investment Management, Inc. | 18.65 % | 30,785,801 |
| Janus Henderson Investors US LLC | 8.288 % | 13,676,976 |
| BlackRock Advisors LLC | 6.621 % | 10,925,776 |
| Fidelity Management & Research Co. LLC | 5.398 % | 8,908,980 |
| Atlas Venture Life Science Advisors LLC | 4.124 % | 6,805,099 |
Catalog · 2026-07-09
Registry officers36
| Name | Role | Since | Shares |
|---|---|---|---|
| Jason Rhodes | Chairman | 2018-10-31 | - |
| Barry Greene | Director/Board Member | 2026-06-21 | - |
| Brian Posner | Director/Board Member | 2025-09-30 | - |
| Brian S. Posner | Director or executive officer | 2025-10-01 | 29,111 |
| Brian S. Posner | Director or executive officer | 2025-10-01 | 29,111 |
| Carlo Incerti | Director/Board Member | 2022-03-01 | - |
| Carlo Incerti, M.D | Director or executive officer | 2022-03-01 | 107,726 |
| Catherine Stehman-Breen | Director/Board Member | 2019-05-31 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 35.73Range 10–50Analysts 15
10Mean 35.7350
- Strong buy 3
- Buy 13
- Strong sell 1
Broker actions40 of 100
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Chardan Capital | Maintained | Buy | 38 | 2026-09-30 |
| HC Wainwright & Co. | Maintained | Buy | 32 | 2026-09-30 |
| Piper Sandler | Reiterated | Overweight | 47 | 2026-09-29 |
| Morgan Stanley | Maintained | Overweight | 36 | 2026-09-09 |
| JP Morgan | Downgrade | Underweight | 10 | 2026-09-09 |
| RBC Capital | Maintained | Outperform | 30 | 2026-09-09 |
| Baird | Maintained | Outperform | 26 | 2026-09-09 |
| Morgan Stanley | Maintained | Overweight | 45 | 2026-07-31 |
| RBC Capital | Maintained | Outperform | 35 | 2026-07-30 |
| Cantor Fitzgerald | Initiated | Overweight | — | 2026-07-23 |
| TD Cowen | Initiated | Buy | — | 2026-06-26 |
| Evercore ISI Group | Maintained | Outperform | 33 | 2026-05-15 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.